Article Type
Article
Changed
Mon, 10/09/2023 - 08:45
Display Headline
Difficult-to-Control Diabetes:
Is Cortisol at Play?

Daniel Einhorn, MD; John Buse, MD, PhD; Ralph DeFronzo, MD; Juan Pablo Frias, MD, and Christopher Lucci, MD, share their insights and perspectives on the connection between difficult-to control T2DM and untreated hypercortisolism:

• Almost a quarter of patients with type 2 diabetes (T2DM) require 3 or more medications to manage their disease, and even then, many patients have difficulty getting their diabetes under control1

• Elevated cortisol activity can exacerbate the pathophysiology of T2DM and can counter the impact of traditional anti-diabetic medications, making diabetes control challenging2-6

• Studies emerging over the last two decades suggest that up to 10% of patients with T2DM may have hypercortisolism7-11

• Patients with treatment-resistant T2DM should therefore be evaluated for hypercortisolism

• Treating the underlying hypercortisolism is important in these patients because managing comorbidities (alone) has not significantly reduced morbidity and mortality12,13

Daniel Einhorn, MD
Meeting Moderator
Vice President
Endocrine Strategy
Corcept Therapeutics
Menlo Park, CA

John Buse, MD, PhD
University of North Carolina
School of Medicine
UNC Diabetes and Endocrinology Clinic
Chapel Hill, NC

Ralph DeFronzo, MD
University of Texas
Health Science Center
San Antonio, TX

Juan Pablo Frias, MD
Velocity Clinical Research
Los Angeles, CA

Christopher Lucci, MD
Diabetes and Cardiovascular of Rockport
Rockport, TX

 

Click HERE to read the supplement.

References

  1. Fang M, et al. N Engl J Med. 2021;384(23):2219-2228.
  2. Scaroni C, et al. Endocr Rev. 2017;38(3):189-219.
  3. Mazziotti G, et al. Trends Endocrinol Metab. 2011;22(12):499-506.
  4. Pivonello R, et al. Neuroendocrinology. 2010;92(suppl 1):77-81.
  5. Mason IC, et al. Diabetologia. 2020;63(3):462-472.
  6. Thau L, et al. StatPearls [Internet]. Updated August 29, 2022. Accessed February 3, 2023. https://www.ncbi.nlm.nih.gov/books/NBK538239/
  7. Chiodini I, et al. Eur J Endocrinol. 2005;153(6):837-844.
  8. Catargi B, et al. J Clin Endocrinol Metab. 2003;88(12):5808-5813.
  9. Costa DS, et al. J Diabetes Complications. 2016;30(6):1032-1038.
  10. Leon-Justel A, et al. J Clin Endocrinol Metab. 2016;101(10):3747-3754.
  11. Steffensen C, et al. Horm Metab Res. 2019;51(1):62-68.
  12. Petramala L, et al. Endocrine. 2020;70(1):150-163.
  13. Morelli V, et al. Front Endocrinol (Lausanne). 2022;13:898084.

©2023 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-01055 SEP 2023

Sponsor
Sponsored by Corcept Therapeutics Incorporated
Publications
MDedge Endocrinology
Sponsor
Sponsored by Corcept Therapeutics Incorporated
Sponsor
Sponsored by Corcept Therapeutics Incorporated

Daniel Einhorn, MD; John Buse, MD, PhD; Ralph DeFronzo, MD; Juan Pablo Frias, MD, and Christopher Lucci, MD, share their insights and perspectives on the connection between difficult-to control T2DM and untreated hypercortisolism:

• Almost a quarter of patients with type 2 diabetes (T2DM) require 3 or more medications to manage their disease, and even then, many patients have difficulty getting their diabetes under control1

• Elevated cortisol activity can exacerbate the pathophysiology of T2DM and can counter the impact of traditional anti-diabetic medications, making diabetes control challenging2-6

• Studies emerging over the last two decades suggest that up to 10% of patients with T2DM may have hypercortisolism7-11

• Patients with treatment-resistant T2DM should therefore be evaluated for hypercortisolism

• Treating the underlying hypercortisolism is important in these patients because managing comorbidities (alone) has not significantly reduced morbidity and mortality12,13

Daniel Einhorn, MD
Meeting Moderator
Vice President
Endocrine Strategy
Corcept Therapeutics
Menlo Park, CA

John Buse, MD, PhD
University of North Carolina
School of Medicine
UNC Diabetes and Endocrinology Clinic
Chapel Hill, NC

Ralph DeFronzo, MD
University of Texas
Health Science Center
San Antonio, TX

Juan Pablo Frias, MD
Velocity Clinical Research
Los Angeles, CA

Christopher Lucci, MD
Diabetes and Cardiovascular of Rockport
Rockport, TX

 

Click HERE to read the supplement.

References

  1. Fang M, et al. N Engl J Med. 2021;384(23):2219-2228.
  2. Scaroni C, et al. Endocr Rev. 2017;38(3):189-219.
  3. Mazziotti G, et al. Trends Endocrinol Metab. 2011;22(12):499-506.
  4. Pivonello R, et al. Neuroendocrinology. 2010;92(suppl 1):77-81.
  5. Mason IC, et al. Diabetologia. 2020;63(3):462-472.
  6. Thau L, et al. StatPearls [Internet]. Updated August 29, 2022. Accessed February 3, 2023. https://www.ncbi.nlm.nih.gov/books/NBK538239/
  7. Chiodini I, et al. Eur J Endocrinol. 2005;153(6):837-844.
  8. Catargi B, et al. J Clin Endocrinol Metab. 2003;88(12):5808-5813.
  9. Costa DS, et al. J Diabetes Complications. 2016;30(6):1032-1038.
  10. Leon-Justel A, et al. J Clin Endocrinol Metab. 2016;101(10):3747-3754.
  11. Steffensen C, et al. Horm Metab Res. 2019;51(1):62-68.
  12. Petramala L, et al. Endocrine. 2020;70(1):150-163.
  13. Morelli V, et al. Front Endocrinol (Lausanne). 2022;13:898084.

©2023 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-01055 SEP 2023

Daniel Einhorn, MD; John Buse, MD, PhD; Ralph DeFronzo, MD; Juan Pablo Frias, MD, and Christopher Lucci, MD, share their insights and perspectives on the connection between difficult-to control T2DM and untreated hypercortisolism:

• Almost a quarter of patients with type 2 diabetes (T2DM) require 3 or more medications to manage their disease, and even then, many patients have difficulty getting their diabetes under control1

• Elevated cortisol activity can exacerbate the pathophysiology of T2DM and can counter the impact of traditional anti-diabetic medications, making diabetes control challenging2-6

• Studies emerging over the last two decades suggest that up to 10% of patients with T2DM may have hypercortisolism7-11

• Patients with treatment-resistant T2DM should therefore be evaluated for hypercortisolism

• Treating the underlying hypercortisolism is important in these patients because managing comorbidities (alone) has not significantly reduced morbidity and mortality12,13

Daniel Einhorn, MD
Meeting Moderator
Vice President
Endocrine Strategy
Corcept Therapeutics
Menlo Park, CA

John Buse, MD, PhD
University of North Carolina
School of Medicine
UNC Diabetes and Endocrinology Clinic
Chapel Hill, NC

Ralph DeFronzo, MD
University of Texas
Health Science Center
San Antonio, TX

Juan Pablo Frias, MD
Velocity Clinical Research
Los Angeles, CA

Christopher Lucci, MD
Diabetes and Cardiovascular of Rockport
Rockport, TX

 

Click HERE to read the supplement.

References

  1. Fang M, et al. N Engl J Med. 2021;384(23):2219-2228.
  2. Scaroni C, et al. Endocr Rev. 2017;38(3):189-219.
  3. Mazziotti G, et al. Trends Endocrinol Metab. 2011;22(12):499-506.
  4. Pivonello R, et al. Neuroendocrinology. 2010;92(suppl 1):77-81.
  5. Mason IC, et al. Diabetologia. 2020;63(3):462-472.
  6. Thau L, et al. StatPearls [Internet]. Updated August 29, 2022. Accessed February 3, 2023. https://www.ncbi.nlm.nih.gov/books/NBK538239/
  7. Chiodini I, et al. Eur J Endocrinol. 2005;153(6):837-844.
  8. Catargi B, et al. J Clin Endocrinol Metab. 2003;88(12):5808-5813.
  9. Costa DS, et al. J Diabetes Complications. 2016;30(6):1032-1038.
  10. Leon-Justel A, et al. J Clin Endocrinol Metab. 2016;101(10):3747-3754.
  11. Steffensen C, et al. Horm Metab Res. 2019;51(1):62-68.
  12. Petramala L, et al. Endocrine. 2020;70(1):150-163.
  13. Morelli V, et al. Front Endocrinol (Lausanne). 2022;13:898084.

©2023 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-01055 SEP 2023

Publications
MDedge Endocrinology
Publications
MDedge Endocrinology
Article Type
Article
Display Headline
Difficult-to-Control Diabetes:
Is Cortisol at Play?
Display Headline
Difficult-to-Control Diabetes:
Is Cortisol at Play?
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
INFORMATION FROM INDUSTRY-SPONSORED CONTENT
Gate On Date
Fri, 08/25/2023 - 11:15
Un-Gate On Date
Fri, 08/25/2023 - 11:15
Use ProPublica
CFC Schedule Remove Status
Fri, 08/25/2023 - 11:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
380517.2
Activity ID
101920
Product Name
Native Clinical Article
Product ID
131
Supporter Name /ID
Korlym [101920 ]